# An Independent Reading Desk, Not a Counter > About This Desk — Research Peptide Fundamentals | The Peptide Train — The Peptide Train is an independent literature digest on Research Peptide Fundamentals research peptides, built around one question: which peptide pairings have actually been studied, and which were only ever assembled? **THE DESK** Who assembles this site, how a page here gets built, and the exact point at which the reporting stops. ## What this desk is The Peptide Train is an independent editorial digest of published research on four peptides — BPC-157, CJC-1295, ipamorelin and tirzepatide — organised around a single question rather than around a catalogue. The question is why these compounds are almost never encountered alone. They arrive coupled: two names in one listing, three in one blend, a bundle presented as though the combination were the unit of study. This desk takes that framing seriously enough to check it, compound by compound, against the literature. Nothing is sold here. No supplier is named, endorsed or ranked. No dose, schedule or pairing is suggested to anyone, and no page on this site is medical advice. Three of the four compounds covered are unapproved research chemicals; the fourth is a prescription medicine whose labelling, not this site, is the authority on how it is used. ## How a page here gets built Every compound page is written from an audited source set rather than from open searching, and every source is numbered on the [reference list](/references). Any figure that appears in the prose — a percentage, a half-life, a participant count, a confidence interval — carries the number of the study it came from, so a reader can go and check it rather than take this desk's word for it. Where the record is thin, the page says so in the same sentence as the finding, not in a footnote. Where the strongest-sounding result comes from rats, the page names the species. Where a claim rests on a single research group without wide independent replication, the page names that too. Community reports are included, because pretending they do not exist is its own kind of distortion, but they are always fenced: labelled as anecdotal, never attached to a dose, and never presented as a substitute for a measured result. Marketing language is not adopted at any point, including the vocabulary the field uses for combining compounds. ## Where the reading stops The most useful thing an editorial desk can do with a subject like this is to be precise about the boundary of what it knows. So: this site does not know whether combining any of these peptides works, and neither does anybody else, because for three of the four no combination has been trialled for any outcome. That is a statement about the evidence, not a verdict on the compounds. Absence of evidence is not evidence of absence, and this desk does not claim a null result it has not got. What can be reported is what was measured, in which species, in how many participants, and with what left over. That is the entire remit. Where a question requires clinical judgement about a particular person, it falls outside it, permanently — and no amount of reading will move that line. Corrections are welcome and are handled on the [contact page](/contact). A source misread is a defect here, not a difference of opinion. --- The Peptide Train follows four habitually bundled peptides back through their own published records and reports the exact point where the reporting has to stop — it sells nothing, prescribes nothing, and endorses no pairing to anyone.